New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:12 EDTTSRO, MYGNMyriad Genetics announces HRD collaboration with TESARO
Myriad Genetics (MYGN) announced that Tesaro (TSRO) will use Myriad's novel HRD, or homologous recombination deficiency, test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase, or PARP, inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
News For MYGN;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
10:05 EDTTSROHigh option volume stocks:
Subscribe for More Information
April 30, 2015
16:18 EDTTSROTESARO reports Q1 EPS ($1.30), consensus ($1.12)
Subscribe for More Information
16:17 EDTTSROTESARO completes targeted enrollment in Phase 3 NOVA trial
Subscribe for More Information
April 21, 2015
06:40 EDTMYGNStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use